Proteasome inhibition prevents experimentally-induced endothelial dysfunction

Life Sciences

Volumn 84, Issue 25-26, 2009, Pages 929-934

  Lorenz, Mario ^a   Wilck, Nicola ^a   Meiners, Silke ^a   Ludwig, Antje ^a   Baumann, Gert ^a   Stangl, Karl ^a   Stangl, Verena ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Endothelial dysfunction; Proteasome inhibition; Reactive oxygen species

Indexed keywords

ACETYLCHOLINE; BENZYLOXYCARBONYLLEUCYLLEUCYLLEUCINAL; COPPER ZINC SUPEROXIDE DISMUTASE; CYCLIC GMP; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; MESSENGER RNA; MG 262; PROTEASOME; PROTEASOME INHIBITOR; RECOMBINANT TUMOR NECROSIS FACTOR ALPHA; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; SUPEROXIDE; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTERY DILATATION; ARTERY ENDOTHELIUM; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; GENE EXPRESSION; MALE; NONHUMAN; PROTEIN EXPRESSION; RAT; UPREGULATION;

ANIMALS; AORTA; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ENZYME INHIBITORS; GENE EXPRESSION REGULATION; MALE; NITRIC OXIDE SYNTHASE TYPE III; PROTEASOME ENDOPEPTIDASE COMPLEX; RATS; RATS, WISTAR; REACTIVE OXYGEN SPECIES; RNA, MESSENGER; TUMOR NECROSIS FACTOR-ALPHA; VASCULAR DISEASES; VASODILATION;

RATTUS;

EID: 67349205896     PISSN: 00243205     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lfs.2009.04.016     Document Type: Article

References (26)

1. Bengtsson S.H., Gulluyan L.M., Dusting G.J., and Drummond G.R. Novel isoforms of NADPH oxidase in vascular physiology and pathophysiology. Clinical and Experimental Pharmacology and Physiology 30 (2003) 849-854
2. Browner N.C., Sellak H., and Lincoln T.M. Downregulation of cGMP-dependent protein kinase expression by inflammatory cytokines in vascular smooth muscle cells. American Journal of Physiology-Cell Physiology 287 (2004) C88-C96
3. Cai H., and Harrison D.G. Endothelial dysfunction in cardiovascular diseases: The role of oxidant stress. Circulation Research 87 (2000) 840-844
4. Chade A.R., Herrmann J., Zhu X., Krier J.D., Lerman A., and Lerman L.O. Effects of proteasome inhibition on the kidney in experimental hypercholesterolemia. Journal of the American Society of Nephrology 16 (2005) 1005-1012
5. Coux O., Tanaka K., and Goldberg A.L. Structure, and functions of the 20S, 26S proteasomes. Annual Review of Biochemistry 65 (1996) 801-847
6. Fukai T. Targeting proteasome worsens atherosclerosis. Circulation Research 101 (2007) 859-861
7. Herrmann J., Saguner A.M., Versari D., Peterson T.E., Chade A., Olson M., Lerman L.O., and Lerman A. Chronic proteasome inhibition contributes to coronary atherosclerosis. Circulation Research 101 (2007) 865-874
8. Keulenaer G.W.D., Alexander R.W., Ushio-Fukai M., Ishizaka N., and Griendling K.K. Tumour necrosis factor alpha activates a p22phox-based NADH oxidase in vascular smooth muscle. Biochemistry Journal 329 (1998) 653-657
9. Kisselev A.F., and Goldberg A.L. Proteasome inhibitors: From research tools to drug candidates. Chemistry & Biology 8 (2001) 739-758
10. Ludwig A., and Meiners S. Targeting of the proteasome worsens atherosclerosis?. Circulation Research 102 (2008) 37
11. Meiners S., Hocher B., Weller A., Laule M., Stangl V., Guenther C., Godes M., Mrozikiewicz A., Baumann G., and Stangl K. Downregulation of matrix metalloproteinases and collagens and suppression of cardiac fibrosis by inhibition of the proteasome. Hypertension 44 (2004) 471-477
12. Meiners S., Laule M., Rother W., Guenther C., Prauka I., Muschick P., Baumann G., Kloetzel P.M., and Stangl K. Ubiquitin-proteasome pathway as a new target for the prevention of restenosis. Circulation 105 (2002) 483-489
13. Meiners S., Ludwig A., Lorenz M., Dreger H., Baumann G., Stangl V., and Stangl K. Nontoxic proteasome inhibition activates a protective antioxidant defense response in endothelial cells. Free Radical Biology and Medicine 40 (2006) 2232-2241
14. Meiners S., Ludwig A., Stangl V., and Stangl K. Proteasome inhibitors: Poisons and remedies. Medicinal Research Reviews 28 (2008) 309-327
15. Mohacsi A., Magyar J., Tamas B., and Nanasi P.P. Effects of endothelins on cardiac and vascular cells: New therapeutic target for the future?. Current Vascular Pharmacology 2 (2004) 53-63
16. Muzaffar S., Jeremy J.Y., Angelini G.D., Stuart-Smith K., and Shukla N. Role of the endothelium and nitric oxide synthases in modulating superoxide formation induced by endotoxin and cytokines in porcine pulmonary arteries. Thorax 58 (2003) 598-604
17. Ohkita M., Takaoka M., Kobayashi Y., Itoh E., Uemachi H., and Matsumura Y. Involvement of proteasome in endothelin-1 production in cultured vascular endothelial cells. Japanese Journal of Pharmacology 88 (2002) 197-205
18. Polytarchou C., and Papadimitriou E. Antioxidants inhibit human endothelial cell functions through down-regulation of endothelial nitric oxide synthase activity. European Journal of Pharmacology 510 (2005) 31-38
19. Quaschning T., Voss F., Relle K., Kalk P., Vignon-Zellweger N., Pfab T., Bauer C., Theilig F., Bachmann S., Kraemer-Guth A., Wanner C., Theuring F., Galle J., and Hocher B. Lack of endothelial nitric oxide synthase promotes endothelin-induced hypertension: Lessons from endothelin-1 transgenic/endothelial nitric oxide synthase knockout mice. Journal of the American Society of Nephrology 18 (2007) 730-740
20. Rock K.L., Gramm C., Rothstein L., Clark K., Stein R., Dick L., Hwang D., and Goldberg A.L. Inhibitors of the proteasome block the degradation of most cell proteins and the generation of peptides presented on MHC class I molecules. Cell 78 (1994) 761-771
21. Russell F.D., Skepper J.N., and Davenport A.P. Evidence using immunoelectron microscopy for regulated and constitutive pathways in the transport and release of endothelin. Journal of Cardiovascular Pharmacology 31 (1998) 424-430
22. Stangl V., Lorenz M., Meiners S., Ludwig A., Bartsch C., Moobed M., Vietzke A., Kinkel H.T., Baumann G., and Stangl K. Long-term up-regulation of eNOS and improvement of endothelial function by inhibition of the ubiquitin-proteasome pathway. FASEB Journal 18 (2004) 272-279
23. Tan M.S., Chai C.Y., Wu J.R., Yeh J.L., Chen I.J., Kwan A.L., Jeng A.Y., Yang H.Y., Lee M.H., and Dai Z.K. Differential change in expression of pulmonary ET-1 and eNOS in rats after chronic left ventricular pressure overload. Experimental Biology and Medicine 23 (2006) 948-953
24. Tasaka K., and Kitazumi K. The control of endothelin-1 secretion. General Pharmacology 25 (1994) 1059-1069
25. Wang P., Ba Z.F., and Chaudry I.H. Administration of tumor necrosis factor-alpha in vivo depresses endothelium-dependent relaxation. American Journal of Physiology-Heart and Circulatory Physiology 266 (1994) H2535-H2541
26. Yoshizumi M., Perrella M.A., Burnett Jr. J.C., and Lee M.E. Tumor necrosis factor downregulates an endothelial nitric oxide synthase mRNA by shortening its half-life. Circulation Research 73 (1993) 205-209